Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7882944 | 0.89 | NR1I2 (0.55) | NR1I2CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL29676427 | 0.82 | NR1I2 (0.65) | NR1I2CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL2615091 | 0.82 | NR1I2 (0.65) | NR1I2CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL2615090 | 0.82 | NR1I2 (0.65) | NR1I2CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL10730517 | 0.82 | MAPT (0.59) | NR1I2CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL6945482 | 0.81 | CACNA1B (0.48) | CACNA1FCACNA1DCACNA1SCACNA1CKDM4E | |
| SCHEMBL3323322 | 0.81 | KDM4E (0.59) | KDM4EHSD17B10ALDH1A1TSHRCYP2C9 | |
| SCHEMBL7887456 | 0.80 | NR1I2 (0.49) | NR1I2CACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL7264460 | 0.80 | ADORA3 (0.67) | CACNA1CKDM4EALDH1A1TSHRKMT2A | |
| SCHEMBL7879285 | 0.79 | CACNA1F (0.76) | NR1I2CACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968574-B2 | Treatment of MCI and Alzheimer's disease | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-05-15 | — | — | US | disclosed |
| WO-2011142778-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110118299-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-05-19 | — | — | US | disclosed |
| WO-2010132671-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292281-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292281-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292281-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | CHAT, CHRM2, TPO | NR1I2 846/4885CACNA1F 335/4885CACNA1D 330/4885 |
| US-20110118299-A1 | TREATMENT OF MCI AND ALZHEIMER'S DISEASE | PSEN1, CHAT, CHRM1 | NR1I2 414/4885CACNA1F 399/4885CACNA1D 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.